Lyra Therapeutics LYRA
LYRA
$0.00 -0.04 (-100.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Lyra Therapeutics (LYRA) Net Equity Issued and Repurchased (2020)

Lyra Therapeutics (LYRA) recorded quarterly Net Equity Issued and Repurchased of $30.4 million in Q1 2020.

Lyra Therapeutics (LYRA) Net Equity Issued and Repurchased (2020) Analysis & Trends

Lyra Therapeutics (LYRA) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $30.4 million the latest figure, recorded in Q1 2020.

  • Net Equity Issued and Repurchased for Q1 2020 came in at $30.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $30.4 million (changed N/A YoY), and the FY2020 annual result was $30.4 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q1 2020 stood at $30.4 million.
  • The five-year high for Net Equity Issued and Repurchased was $30.4 million in Q1 2020, with the low at $30.4 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Lyra Therapeutics 70,995.28 70,995.28 - -

Historic Data

Download Data
DateValue
Mar 31, 2020 30.39 Mn
Mar 31, 2020 30.39 Mn